Evidence map›Paper›PMID 42649216›Full record

ArticleNature communications2026

An ingestible origami-inspired metamaterial for prolonged oral delivery of therapeutics.

Farhad Javid, Sahab Babaee, Jasmine Quigley, Ameya Kirtane, Hormoz Mazdiyasni, Jaimie Rogner, Cody Cleveland, Taylor Bensel, Vance Soares, Joy E Collins and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Farhad JavidDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sahab BabaeeDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jasmine QuigleyDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ameya KirtaneDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Hormoz MazdiyasniDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jaimie RognerDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Cody ClevelandDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Taylor BenselDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Vance SoaresDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Joy E CollinsDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kaitlyn HessDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-2837-0305
Shane McDonnellDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Alison M HaywardDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Robert LangerDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.ORCID 0000-0003-4255-0492
Giovanni TraversoDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.ORCID 0000-0001-7851-4077

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1139921Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) OPP1139937NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244U.S. Department of Health and Human Services (U.S. Department of Health & Human Services) EB000244
6 · The paper itself

Abstract

Poor adherence to oral drug regimens adversely affects treatment outcomes and contributes substantially to preventable healthcare costs, underscoring the need for long-acting drug delivery systems that sustain therapeutic levels over extended periods. To address this, we developed an origami-inspired, oral drug delivery dosage form capable of prolonged residence in the gastric cavity. This system achieves ease of administration and extended gastric residency through geometric design and shape optimization, allowing the dosage form to fold inside a standard ingestible capsule. Upon the capsule's dissolution in the stomach, the dosage form rapidly transforms into its deployed configuration. Our formulation and manufacturing techniques enable the development of a long-acting dosage form with up to 40% weight loading capacity of sample drugs, such as moxifloxacin. The high surface-area-to-volume ratio of the origami design enables approximately linear release kinetics over the observed time window of candidate drugs. We incorporated pH-sensitive elements that dissolve in the neutral portions of the GI tract into the dosage form to promote its dissociation and safe transit in the intestine. In vitro and in vivo studies using swine models demonstrated extended gastric residency of up to three weeks (with a minimum of one week) and an approximately constant release rate for three days. Endoscopic and radiographic evaluations of the animal models confirmed that the dosage forms safely pass through the intestine without causing gastrointestinal obstruction or injury.

Indexed as

Drug Delivery SystemsAdministration, OralAnimalsCapsulesDelayed-Action PreparationsDrug LiberationHydrogen-Ion ConcentrationSwineCapsulesDelayed-Action Preparations

Identifiers

PMID42649216
PMCPMC13518907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.